- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 10.7 EX-10.7 U.S. Supply Agreement
- 10.8 EX-10.8 European Supply Agreement
- 10.13 EX-10.13 Executive Employment Agreement (Wallen)
- 10.14 EX-10.14 Letter Agreement William C. Wallen
- 21 EX-21 Subsidiaries of the Company
- 23.1 EX-23.1 Consent of Pricewaterhousecoopers LLP
- 23.2 EX-23.2 Consent of Arthur Andersen LLP
- 31.1 EX-31.1 Section 302 Certification of C.e.o.
- 31.2 EX-31.2 Section 302 Certification of C.f.o.
- 32.1 EX-32.1 Section 906 Certification of C.e.o.
- 32.2 EX-32.2 Section 906 Certification of C.f.o.
Exhibit 23.2
NOTICE REGARDING CONSENT OF ARTHUR ANDERSEN LLP
IDEXX Laboratories, Inc. (“IDEXX”) was unable after reasonable efforts to obtain the written consent of Arthur Andersen LLP (“Andersen”), IDEXX’s former independent public accountants, to incorporate by reference the report of Andersen, dated January 24, 2002, on the financial statements of IDEXX for the fiscal year ended December 31, 2001. Such report appears herein and in the Annual Report on Form 10-K filed by IDEXX with the Securities and Exchange Commission on March 21, 2002, as required by Section 7 of the Securities Act of 1933, as amended (the “Securities Act”). However, Rule 437a of the Securities Act permits IDEXX to dispense with the requirement to file the written consent of Andersen. As a result, Andersen may not have any liability under Section 11(a) of the Securities Act for any untrue statements of a material fact contained in the financial statements audited by Andersen or any omissions of a material fact required to be stated therein. Accordingly, IDEXX’s stockholders may be unable to assert a claim against Andersen under Section 11(a) of the Securities Act.